Participants in the study will receive the treatment once a week for up to two years. During this time, researchers will monitor the participants’ health to ensure the treatment is safe. The study will involve regular check-ups and assessments to track any changes in the participants’ condition and to identify any potential side effects. The goal is to ensure that the treatment is safe for long-term use in people with this type of lung disease.

Throughout the study, various health measurements will be taken, such as lung function tests and questionnaires about respiratory health. These assessments will help researchers understand how the treatment affects the participants’ lung health and overall well-being. The study aims to provide valuable information that could lead to improved treatment options for individuals with Pulmonary Emphysema due to Alpha-1-Antitrypsin Deficiency.

Participants in the study will receive either the active treatment or a placebo, which is a substance with no active medication. The study will compare two different doses of the treatment, 60 mg/kg and 120 mg/kg, to see which is more effective. The study will last for a period of time, during which participants will have regular check-ups and tests to monitor their lung health and overall well-being.

The main goal is to determine if the treatment can help reduce the progression of lung damage, as measured by a special type of scan called CT densitometry. This scan helps doctors see how much lung tissue is being lost over time. The study will also look at other factors, such as the frequency of severe flare-ups of lung symptoms that require hospitalization. By participating in this study, researchers hope to find a better way to manage and treat Pulmonary Emphysema due to Alpha-1 Antitrypsin Deficiency.

The purpose of the study is to evaluate the long-term safety and tolerability of INBRX-101 in adults with AATD emphysema. Participants in the study will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor participants over a period to observe any side effects and to assess how well the treatment works in managing the condition.

Throughout the study, researchers will keep track of any adverse events, which are any unwanted effects that occur during the treatment. They will also look at changes in lung density using a method called computed tomography (CT), which is a type of imaging that helps visualize the lungs. Additionally, the study will examine how the body processes the treatment and whether any antibodies, which are proteins made by the immune system, develop against INBRX-101. The study aims to provide valuable information on the safety and effectiveness of this treatment for people with AATD emphysema.

The purpose of the study is to evaluate the safety and tolerability of NTLA-3001 in adults with AATD-associated lung disease. Participants will receive a single treatment and will be monitored to see how their bodies respond. The study will look at various aspects, including how the treatment moves through the body and how it affects the levels of certain proteins related to the disease. The study will also check for any immune responses, such as the development of antibodies, which are proteins the body makes to fight off what it sees as foreign substances.

Throughout the study, participants will undergo regular check-ups and tests to ensure their safety and to gather information on how the treatment is working. The trial is designed to provide valuable insights into the potential of NTLA-3001 as a treatment for lung disease associated with Alpha-1 Antitrypsin Deficiency. This research could lead to new ways to manage and treat this condition in the future.

Participants in the study will receive either the new treatment, INBRX-101, or the existing A1PI therapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are unbiased. The study will also include a placebo group, which will receive a solution that does not contain the active treatment. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment.

The study aims to gather information on the safety and effectiveness of INBRX-101 compared to the current standard treatment. It will also look at how the body processes the new treatment and whether it causes any immune reactions. By the end of the study, researchers hope to better understand if INBRX-101 can be a beneficial treatment option for people with AATD emphysema.